Vanda Pharmaceuticals is a biotechnology business based in the US. Vanda Pharmaceuticals shares (VNDA) are listed on the NASDAQ and all prices are listed in US Dollars. Vanda Pharmaceuticals employs 203 staff and has a trailing 12-month revenue of around $177.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.34 |
|---|---|
| 52-week range | $3.30 - $6.75 |
| 50-day moving average | $5.63 |
| 200-day moving average | $4.50 |
| Wall St. target price | $8.11 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.34 from 2024-07-22
| 1 week (2024-07-17) | 1.93% |
|---|---|
| 1 month (2024-06-24) | 6.02% |
| 3 months (2024-04-24) | 39.04% |
| 6 months (2024-01-24) | 72.75% |
| 1 year (2023-07-24) | -1.40% |
|---|---|
| 2 years (2022-07-22) | -42.21% |
| 3 years (2021-07-23) | 19.64 |
| 5 years (2019-07-24) | 13.19 |
| Revenue TTM | $177.6 million |
|---|---|
| Gross profit TTM | $230.1 million |
| Return on assets TTM | -2.43% |
| Return on equity TTM | -0.91% |
| Profit margin | -2.75% |
| Book value | $9.35 |
| Market Capitalization | $355.6 million |
TTM: trailing 12 months
We're not expecting Vanda Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Vanda Pharmaceuticals's shares have ranged in value from as little as $3.295 up to $6.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vanda Pharmaceuticals's is 0.75. This would suggest that Vanda Pharmaceuticals's shares are less volatile than average (for this exchange).
Vanda Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.